Characteristics of Patients With Cancer and COVID-19 Who Discontinued Cancer Treatment

Jessica Y Islam; Cassandra A Hathaway; Emma Hume; Kea Turner; Julie Hallanger-Johnson; Shelley S Tworoger; Marlene Camacho-Rivera

doi:10.1001/jamanetworkopen.2024.11859

Characteristics of Patients With Cancer and COVID-19 Who Discontinued Cancer Treatment

JAMA Netw Open. 2024 May 1;7(5):e2411859. doi: 10.1001/jamanetworkopen.2024.11859.

Authors

Jessica Y Islam^{1

2}, Cassandra A Hathaway², Emma Hume², Kea Turner^{3

4}, Julie Hallanger-Johnson⁵, Shelley S Tworoger^{2

6}, Marlene Camacho-Rivera⁷

Affiliations

¹ Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
² Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
³ Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁴ Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁵ Department of Endocrinology, Mayo Clinic, Rochester, Minnesota.
⁶ Division of Oncological Sciences, School of Medicine, Oregon Health and Science University, Portland.
⁷ Department of Community Health Sciences, School of Public Health, SUNY Downstate Health Sciences University, New York, New York.

No abstract available

Plain language summary

This cross-sectional study evaluates the prevalence of and characteristics associated with discontinuation of cancer treatment among patients who received a diagnosis of COVID-19 during their treatment planning.

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use
COVID-19* / epidemiology
Female
Humans
Male
Middle Aged
Neoplasms* / therapy
SARS-CoV-2*
Withholding Treatment

Substances

Antineoplastic Agents